Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 14Fallopian Tube Neoplasms 13Neoplasms 9Breast Neoplasms 8Prostatic Neoplasms 7Carcinoma, Ovarian Epithelial 7Endometrial Neoplasms 5Pancreatic Neoplasms 4Uterine Cervical Neoplasms 3Recurrence 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Solid Tumor 2Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Metastatic Castration Resistant Prostate Cancer 2Lung Neoplasms 2Leiomyosarcoma 2Carcinoma, Transitional Cell 2Urethral Neoplasms 1Ureteral Neoplasms 1Solid Tumor, Unspecified, Adult 1Sarcoma 1Prostate Cancer Metastatic 1Primary Myelofibrosis 1Pathologic Complete Response 1Myeloproliferative Disorders 1

Interventions

talazoparib 1rucaparib 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ATM Gene Mutation × rucaparib × Clear all
NCT03442556 2025-06-12

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

University of Washington

Phase 2 Terminated
18 enrolled
Genitourinary

ATM Gene Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡